- Home
- ESNT vs BDTX Comparison
ESNT vs BDTX Comparison
Compare ESNT & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ESNT | BDTX |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 171.9M |
| IPO Year | 2013 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ESNT | BDTX |
|---|---|---|
| Price | $68.79 | $2.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | ★ $67.29 | $9.67 |
| AVG Volume (30 Days) | 516.4K | ★ 521.4K |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.19% | N/A |
| EPS Growth | 0.73 | ★ 130.71 |
| EPS | ★ 3.89 | N/A |
| Revenue | ★ $1,260,935,000.00 | N/A |
| Revenue This Year | $1.12 | N/A |
| Revenue Next Year | $3.37 | N/A |
| P/E Ratio | $17.78 | ★ N/A |
| Revenue Growth | ★ 1.45 | N/A |
| 52 Week Low | $55.34 | $1.60 |
| 52 Week High | $70.37 | $4.94 |
Technical Indicators
Market Signals| Indicator | ESNT | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 53.83 | 52.18 |
| Support Level | $67.89 | $1.96 |
| Resistance Level | $70.19 | $2.28 |
| Average True Range (ATR) | 1.05 | 0.10 |
| MACD | -0.15 | -0.02 |
| Stochastic Oscillator | 59.08 | 26.97 |
Price Performance
Historical ComparisonAbout ESNT Essent Group Ltd.
Essent Group Ltd serves the housing finance industry by providing private mortgage insurance, reinsurance, risk management products, title insurance, and settlement services to mortgage lenders, borrowers, and investors to support homeownership. It provides credit protection to lenders and mortgage investors by covering a portion of the unpaid principal balance of a mortgage and certain related expenses in the event of a default. By providing capital to mitigate mortgage credit risk, the company allows lenders to make additional mortgage financing available to prospective homeowners.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.